REGENXBIO INC. (RGNX)
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
📈 **POSITIVE** • Medium confidence analysis (75%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business